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The therapeutic potential of a nucleoside analog, gemcitabine, is severely compromised due to its rapid
clearance from systemic circulation by enzymatic degradation into an inactive metabolite. In the present
investigation, micelles based on polymer–drug conjugate were developed for gemcitabine and
investigated for their potential to improve cancer chemotherapy. The tocopherol poly(ethylene glycol)
succinate 1000 (TPGS)–gemcitabine prodrug was synthesized via an amide linkage and characterised by
analytical methods, including FT-IR, 1H NMR, and MALDI-TOF. The micellar formulation of TPGS–
gemcitabine prodrug was developed by a self-assembly technique and evaluated for various
physicochemical parameters including particle size, polydispersity, morphology, critical micelle
concentration and release proﬁle. It was observed that gemcitabine present in TPGS–gemcitabine
micelles was resistant to deamination by crude cytidine deaminase. The improved cytotoxicity of the
micellar formulation was observed using TPGS–gemcitabine micelles against pancreatic cancer cells.
Further, it was found that, unlike native gemcitabine, nucleoside transporters were not required for
TPGS–Gem micelles to demonstrate their anticancer potential. These ﬁndings revealed that TPGS–
gemcitabine micelles may serve as a promising platform for gemcitabine in order to improve its
anticancer eﬃcacy.1. Introduction
Pancreatic cancer is known as the most lethal malignant
disease.1 Despite the therapeutic advances, 80–85% of cases are
detected in a highly metastatic state, and complicated to treat
with a median survival of <6 months.2 The anatomy and biology
of pancreatic cancer also conspire to elude detection and resist
eradication.3 Gemcitabine is a strong cytidine analog approved
by the FDA for the management of pancreatic cancer and
a variety of solid tumours.4 At present, gemcitabine is used as
a single agent for the therapy of advanced pancreatic cancer and
is the most prescribed anticancer drug worldwide, in spite of
growing resistance.5,6 In recent years, several trials have
demonstrated the eﬃcacy of targeted therapy or combination
chemotherapy, however, none of them has resulted in a change
in the practice of gemcitabine monotherapy.7,8 Moreover, the
clinical eﬃcacy of gemcitabine is also compromised by its rapid
clearance through enzymatic metabolism driven by cytidineine, Keele University, Keele, Staﬀordshire,
, CSIR-Indian Institute of Integrative
1
tion (ESI) available. See DOI:
7deaminase (CDA), which is ubiquitously expressed in the liver
and blood plasma.9,10 The high degree of hydrophilicity of
gemcitabine further decreases its eﬃcacy by restricting its
permeation of the dense vasculature exterior of the tumour.
Therefore, a high drug dose is required to achieve therapeutic
concentration or desired eﬀect, which causes serious side
eﬀects.
Many eﬀorts have been employed to advance the eﬃciency of
gemcitabine, including nanoparticles,11,12 liposomes,13,14
micelles,15,16 polymer–drug conjugates (Prodrugs).17,18 Besides
other eﬀorts, gemcitabine prodrugs received a constant recog-
nition for its enhance metabolic stability, improved cellular
uptake or cytotoxicity and to limit the resistance. Various
chemically modied prodrugs of gemcitabine were reported
either employing hydrophilic polymers, includes polyethylene
glycol (PEG)18 and poly-glutamic acid (PGA)19 or lipophilic
agents such as linoleic acid20 and squalene.21 Moreover,
amphiphilic polymer–drug conjugates or lipophilic prodrug
conjugates are more attractive due to their self-assembling
characteristics into nano-micelles upon dilution with water.
Micelles, based on polymer–drug conjugate (prodrug) is an
exciting development of polymeric drug delivery systems and
have dual benets arising from the polymer–drug conjugate
itself as well as the properties gained from micellar formula-
tions. Various gemcitabine formulations based on anThis journal is © The Royal Society of Chemistry 2016
Paper RSC Advances
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 1
5 
Ju
ne
 2
01
6.
 D
ow
nl
oa
de
d 
on
 1
1/
21
/2
01
9 
9:
33
:5
4 
A
M
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n-
N
on
Co
m
m
er
ci
al
 3
.0
 U
np
or
te
d 
Li
ce
nc
e.
View Article Onlineamphiphilic polymers or lipid-based micelles have been re-
ported to possess improved eﬃcacy of gemcitabine. Chitkara
et al.22 reported gemcitabine conjugated poly(ethylene glycol)-
block-poly(2-methyl-2-carboxyl-propylenecarbonate) (PEG–PCC)
self-assembled micelles improves plasma stability and in vivo
eﬃcacy of gemcitabine against MiaPaCa-2 cells derived xeno-
gra tumour in mice. In another study, Daman et al.15
compared the in vitro eﬃcacy of 4-(N)-stearoyl gemcitabine
(GemC18) loaded PEG–PLGA micelles and 4-(N)-stearoyl gem-
citabine self-assembled micelles against pancreatic cancer and
reported the higher eﬃcacy of self-assembled 4-(N)-stearoyl
gemcitabine micelles. Recently, Han et al.23 demonstrated the
high cytotoxicity of gemcitabine conjugated PEG-b-[PLA-co-
PMAC-gra-(IR820-co-GEM)] self-assembled theranostic
micelles in BxPC-3 cells and higher accumulation in the tumour
tissue.
To extend this concept of self-assembled micelles based on
amphiphilic polymer–drug conjugate, in the present investiga-
tion, we have designed a gemcitabine prodrug in which drug is
conjugated with such amphiphilic polymer, which possesses
additional therapeutic values. D-Alpha-tocopherol polyethylene
glycol succinate (TPGS) was used as an amphiphilic polymer to
synthesize gemcitabine prodrug. TPGS is an amphiphilic
derivative of natural vitamin E (a-tocopherol), synthesized by
graing a-tocopherol with polyethylene glycol oligomer via
a succinate linker and gained interest in the development of
drug delivery systems.24 TPGS has been permitted by FDA as
a drug solubiliser, in a variety of formulations and listed as
a GRAS (generally referred as safe) supplement, also used as an
absorption enhancer and stabiliser.25,26 It has been reported
that TPGS acts as an anticancer agent alone or synergistically
with chemotherapeutic drugs.27–31 Recently, Neophytou et al.
investigated that the intrinsic anticancer activity of TPGS is due
to the inhibition of phospho-AKT and the downregulation of the
anti-apoptotic proteins survivin and Bcl-2.27 In addition, it has
been reported that the inhibition of survivin expression in
pancreatic cancer could potentiate the activity of gemcitabine
signicantly.32,33
Previously we have investigated the potential of poly(lactide-
co-glycolide)–gemcitabine prodrug conjugate in an attempt to
improve the eﬃcacy of gemcitabine.17 In this work, we synthe-
sized TPGS–gemcitabine (TPGS–Gem) prodrug to protect the
drug from enzymatic metabolism. The TPGS–Gem prodrug was
characterized for self-assembly properties to explore their
potential as drug delivery carrier for improved eﬃcacy of
gemcitabine.
2. Experimental
2.1 Materials
Gemcitabine was purchased from Fluorochem (UK). Tocopherol
poly(ethylene glycol) succinate 1000, dimethylamino pyridine,
succinic anhydride, N-hydroxysuccinimide (NHS), N,N0-dicyclo-
hexyl carbodiimide (DCC), dry dichloromethane, diethyl ether
and ethanol were purchased from Sigma-Aldrich (UK). MTT (3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide)
was purchased from Santa Cruz Biotechnology (Santa Cruz, CA).This journal is © The Royal Society of Chemistry 2016Recombinant human cytidine deaminase (specic activity 3.5
unit per mg) was obtained from ProSpec (USA). The human
pancreatic cancer cells (BxPC-3) were procured from European
Collection of Cell Cultures (ECACC, LGC Standards, UK) and
grown in complete growth medium, Roswell Park Memorial
Institute medium (RPMI) supplemented with 10% fetal bovine
serum and 1% penicillin streptomycin procured from Gibco
BRL (Life Technologies, UK).
2.2 Synthesis of TPGS–gemcitabine prodrug
The TPGS–Gem prodrug was synthesized in a two-step process.
The rst step involves functionalization of TPGS with the
terminal free carboxyl group by esterication through succinic
anhydride (SA) and a catalytic amount of dimethylamino pyri-
dine (DMAP).34 Subsequently, the second step involves the
amidation of an amino group on gemcitabine with functional-
ised carboxyl group of TPGS. The schematic illustration of the
synthetic route is shown in Fig. 1. In brief, TPGS (1 equivalent),
succinic anhydride (2 equivalent), and dimethylamino pyridine
(1 equivalent) were dissolved in dry dichloromethane (DCM)
and reacted under a nitrogen atmosphere for 24 h at room
temperature (RT). The reaction mixture was ltered and
precipitated in cold diethyl ether and dried under vacuum. The
precipitated product was taken up in DCM and dialyzed (Pur-A-
Lyzer dialysis kit, MWCO 1000, Sigma) against 50 : 50 mixture
of ethanol : water for 72 h to remove excess amount of DMAP
and SA. The TPGS–SA was dried under vacuum and stored at
20 C until further use.
The conjugation of the amino group of gemcitabine and
carboxyl group of TPGS–SA was achieved by classical carbodii-
mide coupling reaction. In brief, TPGS–SA (1 equivalent), di-
cyclo hexyl carbodiimide (DCC, 2 equivalent), N-hydroxy-
succinimide (NHS, 2 equivalent) was dissolved in anhydrous
DMSO and reacted for 24 h at RT under nitrogen conditions.
The reaction was ltered using 0.45 mm syringe lter, to remove
the by-product N,N-dicyclohexylurea. The ltrate was mixed
with a solution containing gemcitabine (2 equivalent of TPGS–
SA) and triethylamine (2 equivalent) in DMSO and kept under
stirring for further 24 h in a nitrogen environment at RT. The
reaction mixture was dialysed (Pur-A-Lyzer dialysis kit, MWCO
1000, Sigma) against DMSO to remove unreacted gemcitabine
for 24 h. Aerward, the dialyzingmedia was replaced by water to
remove DMSO and reaction mixture was freeze-dried to obtain
TPGS–Gem prodrug.
2.3 Characterization of TPGS–gemcitabine prodrug
The conjugation between TPGS and gemcitabine was validated
by diﬀerent analytical methods including Fourier transform
infrared (FT-IR) spectroscopy and nuclear magnetic resonance
(NMR) spectroscopy and MALDI-TOF spectroscopy. The FT-IR
spectra for TPGS, TPGS–SA gemcitabine and TPGS–Gem pro-
drug were recorded from Perkin Elmer, FT-IR spectrometer.
Neat samples were analyzed to detect IR bands over a range
3500–800 cm1. 1H NMR spectrum of native gemcitabine, TPGS,
TPGS–SA, and TPGS–Gem, were acquired on a Bruker DRX 300
MHz NMR spectrometer. Tetramethylsilane was used as anRSC Adv., 2016, 6, 60126–60137 | 60127
Fig. 1 A schematic representation of the reaction involved in the synthesis of tocopherol polyethylene glycol succinate 1000 (TPGS)–gemci-
tabine prodrug.
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View Article Onlineinternal standard. A mass spectrum of native TPGS, TPGS–SA,
and TPGS–Gem were obtained by MALDI-TOF (Applied
Biosystems/AB Sciex) equipped with ND-YAG diode pump laser
(355 nm/200 Hz). The instrument was run in a positive ion
reection mode using CHCA (a-cyano-p-hydroxycinnamic acid)
as a matrix. Respective peptide standards were used to calibrate
the mass range. The spectra were recorded in the range of 800 to
2400 Da.2.4 RP-HPLC analysis
The content of gemcitabine conjugated to TPGS–gemcitabine
prodrug was determined using RP-HPLC method.35 Alkaline
hydrolysis was performed in KOH 0.1 N to separate the native
gemcitabine from TPGS moiety. In brief, 1 mg ml1 concen-
tration of TPGS–Gem was incubated with 0.1 N of KOH at 40 C
for 1 h. Samples were appropriately diluted with acetonitrile
and the amount of gemcitabine quantied by HPLC (Perkin
Elmer) analysis. The samples were analyzed using HPLC
equipped with RP-18 column (E-Merck, 5 mm, 4.0  250 mm)60128 | RSC Adv., 2016, 6, 60126–60137with PDA detector. Acetonitrile and 0.02 M ammonium acetate
buﬀer (1 : 1) was used asmobile phase at ow rate 0.5mlmin1.
The detection wavelength (lmax) for gemcitabine was 268 nm
and retention time of gemcitabine was found to be 4.08 min.
2.5 Preparation of TPGS–gemcitabine prodrug micelles
TPGS–Gem prodrug micelle was prepared by a simple solvent
evaporation method with minor modications.36 Briey, 30 mg
of TPGS–Gem prodrug was solubilized in 1.5 ml of ethanol and
added drop-wise to 15 ml of ultra-puried water under stirring.
The solution was stirred gently on magnetic stirrer to evaporate
organic solvent. The resultant mixture was ltered by 0.45 mm
poly(ethersulfone) syringe lter. For storage, the micelles were
freeze dried and kept refrigerated until further use.
2.6 Micelles characterization
The average particle size, size distribution, polydispersity index
(PDI) and surface charge of prepared micelles were determined
through dynamic light scattering (DLS) (Zetasizer, ZS-Nano,This journal is © The Royal Society of Chemistry 2016
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View Article OnlineMalvern, UK). The particle size measurement was performed
using disposable poly(styrene) cells, the micelle solution was
incubated at various temperatures (25–40 C) for 10 min to
attain the equilibrium. The zeta potential of micelles solution
was measured using plain folded zeta cells, at 25 C on xed
scattered light at an angle 90. All measurements were per-
formed in triplicate. The morphological investigation of
prepared micelles was performed using JEOL JEM-1230 trans-
mission electron microscope (JEOL, Japan). A drop of the
micellar formulation was carefully placed on the formvar-
coated copper grid (200 mesh) and then dried at room
temperature overnight before observation on the microscope.
2.7 Critical micelle concentration using UV hydrophobic
probes
The critical micelle concentration (CMC) of TPGS–Gem prodrug
was investigated by UV hydrophobic probe, methyl orange, as
described by Uchegbu et al.37 In brief, a methyl orange (25 mM)
stock solution was prepared using sodium tetraborate buﬀer
(0.02 M, pH 9.4) in deionised water. A solution of 10 mg ml1
concentration of TPGS–Gem prodrug was prepared in methyl
orange solution. Various concentration (0.015–2.5 mg ml1) of
TPGS–Gem was prepared by serial dilution of prodrug solution
using methyl orange stock as diluent. Each concentration was
scanned in the UV-visible spectrophotometer (UV-2600, Shi-
madzu) between 350 and 600 nm and maximum absorbance
(lmax) was registered. The lmax of aqueous methyl orange stock
solution was recorded as control (i.e. 0 mg ml1 surfactant). A
graph was plotted between lmax vs. surfactant concentration.
The CMC is identied as the inection point (hypsochromic
shi) at the beginning of the curve on the graph plotted against
lmax vs. TPGS–Gem concentration.
2.8 In vitro drug release
In vitro drug release study of TPGS–Gemmicelles was performed
in buﬀer solution with pH 7.4 at various temperatures i.e. 30, 37
and 40 C. In brief, 3 ml of TPGS–Gem micelle solution was
placed in a dialysis bag (MWCO 1000) and immersed with 20 ml
of buﬀer solutions in a shaker incubator at temperature 30, 37
and 40 C. At scheduled time intervals, 100 ml of the sample was
collected from buﬀer solution and replaced with the same
amount of fresh buﬀer of the same temperature. The collected
samples were analyzed by validated RP-HPLC method reported
above. Experiments were performed in triplicates for up to one
week.
2.9 Stability studies with cytidine deaminase
The TPGS–Gem micelles and native gemcitabine were exposed
to cytidine deaminase, in order to evaluate the metabolism
triggered by the enzyme. Briey, 0.4 mM concentration of
TPGS–Gem micelles and gemcitabine were prepared in 0.1 M
Tris buﬀer (pH 7.5) with respect to gemcitabine concentration.
The reactions were initiated by addition of 10 ml of recombinant
human cytidine deaminase, dissolved 20 mM Tris-buﬀer, 2 mM
EDTA and 40% glycerol in 1 ml of each solution. At various time
points, 60 ml of aliquots were collected mixed with 30 ml ofThis journal is © The Royal Society of Chemistry 2016acetonitrile to terminate the enzyme activities. The solvent of
the reaction mixture was evaporated using freeze drying. The
dried sample was reconstituted in 100 ml of water and analyzed
by LC-MS/MS using the method described in our previous
report.17
2.10 Cell culture methods
BxPC-3 cells were cultured using RPMI medium supplemented
with 10% fetal bovine serum (FBS) and 1% antibiotic (strepto-
mycin and penicillin) solution in 50 ml cell culture ask. Cells
were cultivated in a humidied incubator with 5% carbon
dioxide at 37 C. Aer 90% conuence level reached, cells were
routinely trypsinised and subcultured.
2.11 In vitro cytotoxicity
For evaluation of the cytotoxic potential of TPGS–Gemmicelles,
MTT assay was performed in comparison with gemcitabine and
placebo TPGS micelles (i.e. TPGS micelles with no drug conju-
gated, in equivalent weight as in TPGS–Gem micelles) at incu-
bation time 24 h, 48 h, and 72 h. BxPC-3 cells were seeded for 24
h in 96 well at bottom plates (Corning, USA) at a density of 15
 103 cells per well in RPMI medium. Various concentrations of
test samples were added to the cells and incubated for pre-
determined time intervals. Aer completion of the incubation
period, themediumwas replaced with 100 ml of MTT dye to each
well at 0.5 mg ml1 concentration and incubated for 4 h. The
degree of cell viability is expressed by translation of MTT into
purple formazan crystals by metabolically viable cells. The
produced formazan crystals were dissolved using 100 ml of
DMSO and optical density of wells was measured at wavelength
570 nm spectrophotometrically (BioTek, Synergy HT). The
nonlinear regression analysis was performed to determine
a concentration caused a 50% inhibition in the control growth
rate (IC50) using Graph Pad soware.
2.12 Nucleoside transporter inhibition
Gemcitabine typically enters across the cellular membrane
through nucleoside transporter (hENT and/or hCNT).38 Since
one or more of these nucleoside transporters are essential for
gemcitabine to enter the cell, we performed a nucleoside
transporter inhibition assay, to investigate whether TPGS–Gem
micelles also dependent on nucleoside transporter. The MTT
assay was performed as mentioned above with minor changes.
BxPC-3 cell suspension was seeded in 96 well at bottom plates
and incubated for 24 h. A 10 mM concentration of dipyridamole
(a nucleoside transporter inhibitor) was incubated with cells
prior to sample addition to inhibiting the hENT-1 transporter.
The IC50 values were calculated to determine the eﬀect of
inhibition of nucleoside transporters.
2.13 Cellular uptake
A cellular uptake study was performed to demonstrate the
internalization of TPGS–Gem micelles in the presence and
absence of nucleoside transporter inhibitor, dipyridamole.
Coumarin-6 loaded TPGS–Gem micelles was prepared by sameRSC Adv., 2016, 6, 60126–60137 | 60129
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View Article Onlinemethod as described for TPGS–Gem micelles, except that
coumarin-6 was added in rst step with the prodrug in ethanol.
BxPC-3 cells were seeded onto a borosilicate glass cover slip in
six well plates for 24 h. Then the media of three wells was
replaced with a 10 mM concentration of dipyridamole to inhibit
the nucleoside transporters, 30 min before the addition of test
samples. Aerwards the media of all six wells was substituted
with 0.125 mg ml1 of coumarin-6 loaded TPGS–Gem micelles
and incubated for 4 h at 37 C in CO2 incubator. Aer
completion of incubation time the cells were washed twice by
PBS (pH 7.4) and xed with 70% ethanol and the nuclei was
counter stained by DAPI (4,6 diamidino-2-phenyl indole). Then
the cells were observed under uorescence cell imaging station
(EVOS FLoid).2.14 AFM topography
The eﬀect of morphological changes was assessed aer treat-
ment with TPGS–Gem micelles, gemcitabine, and native TPGS
using atomic force microscope aer 24 h of incubation. BxPC-3
cells were seeded in 6 well plates over coverslips. Cells were
incubated in a humidied incubator at 37 C and 5% CO2
atmosphere. Aer 24 h, the media was replaced with a 10 mM.
The concentration of gemcitabine and TPGS–Gem micelles
dissolved in media and incubated for 24 h. The control cells
were treated with media only. Aerward, the media was
removed and cells were washed abundantly with PBS and xed
using 2.5% solution of glutaraldehyde prepared in PBS for 10
min. Aer xation cells were again washed 5–6 times with PBSFig. 2 Stacked Fourier transform-infrared (FT-IR) spectra of TPGS, gemc
800 cm1.
60130 | RSC Adv., 2016, 6, 60126–60137and mounted on a glass slide. Cell topography was imaged
using a Bruker Bio Catalyst atomic force microscope (Bruker,
Germany) using Peak Force Tapping Mode and a Scan Asyst in
air cantilever.
3. Results and discussion
The TPGS–Gem micelle was prepared aer synthesis of TPGS–
Gem prodrug. The gemcitabine was conjugated to TPGS
through a succinate linker as a two-step process: (I) modica-
tion of end group of TPGS to a carboxylic group using succinic
anhydride and (II) coupling of activated ester form of succinic
acid-modied TPGS to the amino group of gemcitabine using
classical carbodiimide chemistry, as shown in Fig. 1. All the
reactions performed to synthesize TPGS–Gem prodrug were
characterized by diﬀerent analytical techniques including FT-
IR, 1H NMR, and MALDI-TOF.
3.1 Characterization of TPGS–Gem prodrug
3.1.1 Fourier transform infrared spectra. The FT-IR spectra
of native TPGS (Fig. 2) showed a characteristic band on 1736
cm1 is attributed to the carbonyl group present in the TPGS. In
the FT-IR spectra of TPGS–SA the strong absorption of carbonyl
band at 1732 cm1 was observed, which conrmed the forma-
tion of TPGS–SA, these ndings are in accordance with previous
reports.34,39 Moreover, in the FT-IR spectra of gemcitabine, the
band found at 1674 cm1 and 1662 cm1 attributed as a char-
acteristic amine bending vibrations. In contrast, the FT-IR
spectra of TPGS–Gem prodrug showed the characteristicitabine and TPGS–Gem prodrug scanned in the region of 3500 cm1 to
This journal is © The Royal Society of Chemistry 2016
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View Article Onlinecarbonyl band at 1734 cm1, in addition, bands at 1654 cm1
and 1560 cm1 represents amide I (C]O, stretching) and amide
II (N–H bending), respectively, conrmed the formation of
amide bond between terminal carboxyl group of TPGS and
primary amino group of gemcitabine.17
3.1.2 Nuclear magnetic resonance spectroscopy. The
structure of TPGS–Gem prodrug was also corroborated by 1H
NMR spectra (Fig. 3). In the 1H NMR spectrum of TPGS, the
signals of ethylene protons of PEG chain, present in TPGS were
observed at d 3.5–3.6. The signals registered in the aliphatic
region (d 1–3) of spectra attributed to the various protons of
vitamin E-tail. 1H NMR spectra of TPGS–SA showed similar
signals as observed in the spectra of TPGS except succinyl
methylene (–CH2) protons at d 2.6–2.7, conrmed the reaction
between TPGS and succinic anhydride.34 In the 1H NMR spec-
trum of gemcitabine, peaks at d 8.2 correspond to the protons of
a 4-amino group of gemcitabine. Other characteristic signals of
50 and 30OH of gemcitabine was registered at d 6.08 and 6.28
respectively.20 The 1H NMR spectra of TPGS–Gem prodrug
showed the characteristic ethylene protons of PEG chain at d 3.5
with various protons of vitamin E-tail. However, the peak of the
amino group of gemcitabine was shied from d 8.2 to d 11.2
suggested the formation of an amide bond between gemcita-
bine and TPGS.20,40
3.1.3 MALDI-TOF mass spectroscopy. The MALDI-TOF
spectra of TPGS, TPGS–SA and TPGS–Gem was investigated toFig. 3 Stacked 1H NMR (400 MHz) spectra of TPGS, TPGS–SA, gemcit
internal standard.
This journal is © The Royal Society of Chemistry 2016assign the formula of various oligomeric compositions with
diﬀerent adduct and charge states (Fig. 4). The molecular
formula of TPGS forming potassium adduct was validated as
C33H54O5–(CH2CH2O)n + K. In theMALDI spectrum of TPGS–SA,
a marked 100 Da increment in the mass of various oligomers
was observed, which is equal to the mass of succinic anhydride,
suggesting the reaction between TPGS and succinic anhydride.
An expected empirical formula for various oligomers of TPGS–
SA forming potassium adduct could be [C33H53O5–(CH2CH2-
O)n]–CO–C2H4–COOH + K. Moreover, the MALDI spectra of
TPGS–Gem prodrug showed an increment of 245 Da in oligo-
meric clusters as compared to the oligomers of TPGS–SA, which
is similar to the increment of mass if gemcitabine conjugated to
TPGS–SA via an amide bond. However, there was no adduct
(including K, Na) seen in the oligomeric clusters of TPGS–Gem
spectra. Furthermore, in the spectra of TPGS and TPGS–SA the
oligomers presents in diﬀerent charge state.
For instance, the reaction between TPGS oligomer with n-
value 20, [C33H54O5–(CH2CH2O)20, 1411 Da; or m/z 1450 in the
potassium salt form] occurs with succinic acid would lead to
the species at m/z 1511 (or m/z 1550 in the form of potassium
salt) and further reaction with gemcitabine would lead to the
species at 1757 (with no adduct formation). By comparing the
spectra of TPGS, TPGS–SA and TPGS–Gem an increment of the
abundance of the ion at 1550 in TPGS–SA and 1757 in the
spectra of TPGS–Gem is clearly visible, conrmed theabine, and TPGS–Gem micelles registered using trimethylsilane as an
RSC Adv., 2016, 6, 60126–60137 | 60131
Fig. 4 Full mass overview spectra's of TPGS (A), TPGS–SA (B) and
TPGS–Gem prodrug (C) by MALDI-TOF.
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View Article Onlinetransformation of the terminal hydroxyl group to the carboxyl
group at TPGS terminal end aer I step of reaction and
formation of an amide bond between TPGS–SA and gemcita-
bine aer II step. The similar behavior was noticed for all other
oligomeric species. The concise table of proposed formulas of
oligomeric compositions of TPGS–Gem prodrug and inter-
mediates is given in ESI.† The conjugation of gemcitabine to
TPGS is an important consideration since gemcitabine as
a hydrophilic drug have very low encapsulation eﬃciency in
polymeric nanoparticles. TPGS–Gemmicelles could be used as
a new strategy to deliver hydrophilic drug if the loading eﬃ-
ciency is high. The amount of drug conjugated to TPGS was
calculated to be 36.3  2.5 mg mg1 of TPGS–Gem prodrug,
which is higher than our previous investigation (i.e. 0.124 mol
of gemcitabine per mol of PLGA) in which an antiproliferative
activity of PLGA–gemcitabine polymeric conjugate was
demonstrated.1760132 | RSC Adv., 2016, 6, 60126–601373.1.4 Micelle generation and characterization. The TPGS–
Gem micelles were generated by simple solvent evaporation
method as described above. The amphiphilic TPGS–Gem pro-
drug generates micelles by self-assembly in aqueous solution.
Aer evaporation of the solvent, the generated micelles were
characterised using various physicochemical parameters.
3.1.5 Particle size, zeta-potential and morphological anal-
ysis. The average particle diameter of TPGS–Gem prodrug was
investigated upon nano-aggregation into micelles at diﬀerent
temperatures (25, 30, 35, 40 C). No signicant alteration was
observed in the hydrodynamic diameter at selected tempera-
tures, suggested that temperature does not inuence the
average particle size of micelles. An average particle size at 25
C was measured as 15.09  0.7 nm (Fig. 5A) with poly-
dispersity index, 0.078  0.025. Further at higher temperature
the change in size of TPGS–Gemmicelles has been observed to
be negligible and the average hydrodynamic was registered as
15.67  0.16, 15.38  0.34, 15.94  0.59 and PDI 0.19  0.02,
0.115  0.037, 0.153  0.032 respectively, at temperature 30
C, 35 C and 40 C. The zeta potential of the micelles was
evaluated as 9.3  0.61 mV (Fig. 5B). Particle size and zeta
potential are the key factors for achieving the therapeutic
eﬃcacy of nanomedicines and micelles typically between 10
nm and 100 nm are known to be favorable for drug delivery in
cancer therapy.41 Particles smaller than 10 nm in size will be
rapidly abolished through renal clearance (threshold < 6 nm)
and greater than 100 nm, have a probability to uptake by
reticuloendothelial system (RES).42 Moreover, either neutral or
anionic surface charge is considered benecial for nano-
carriers for successful evasion of renal elimination could
result long circulatory action in vivo.43 The transmission
electron microscopy (TEM) was used to determine the
morphology of TPGS–Gemmicelles; from which it can be seen
that micelles have generally spherical shape (Fig. 5C),
however, a slightly bigger than the particle size was observed
with DLS. The diﬀerence in the size obtained by two tech-
niques could be due to the melting property of TPGS (melting
point-38 C). The micelles experience a certain extent of
melting and expansion in size due to a high energy electron
beam in TEM which makes them appear bigger in the images
captured by TEM.44
3.1.6 Critical micelle concentration. The CMC value of
TPGS–Gem prodrug and native TPGS was investigated using
methyl orange as a hydrophobic probe in aqueous solution by
monitoring the hypsochromic shi in methyl orange UV spectra
(Fig. 5D). Methyl orange has lmax at 464 nm in the presence of
UV light. When a surfactant was diluted in methyl orange
solution, it favours the hydrophobic core formed from the
micelles of the amphiphilic polymers and a hypsochromic shi
was experienced at critical micelle concentration value on UV
spectra of amphiphilic polymer or surfactant.45 The eﬀect of
concentration of TPGS–Gem prodrug on the peak absorption of
methyl orange at lmax 464 nm is given in the Fig. 5D. The native
TPGS exhibited the CMC value at 0.2 mg ml1 (0.02%)39,46 and it
was observed that the CMC value of TPGS–Gem prodrug was
0.15 mg ml1 (0.015%). The lower CMC value of micellesThis journal is © The Royal Society of Chemistry 2016
Fig. 5 Representative particle size distribution (A) and zeta potential (B) of TPGS–Gem micelles measured by dynamic light scattering
measurement at ﬁxed 90 angle at 25 C using disposable polystyrene cells and folded capillary cells respectively. (C) Transmission electron
micrograph of TPGS–Gem micelles revealing size of micelles captured using a formvar-coated copper grid (D). Critical micelle concentration
measurement of TPGS–Gem micelles using methyl orange as hydrophobic probe, inﬂexion point in the graph represents the CMC value.
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View Article Onlineindicated high stability, which prevents its dissociation into
unimers upon dilution with large blood volume.
3.1.7 In vitro drug release. The rate of gemcitabine release
from TPGS–Gem micelles was evaluated in PBS buﬀer (pH 7.4)
at various temperatures (30, 37 and 40 C). As illustrated in
Fig. 6 the release of gemcitabine from prodrug micelles showed
signicantly slower release at 30 C than that at 37 and 40 C.
However, a lower increment of drug release at temperature 40
C was observed than that of drug release at 37 C. Under all
temperatures the release of gemcitabine began as an initial slow
release (2.4% at 30 C, 8.5% at 37 C and 10% at 40 C in 1 h)
followed by a continued sustained release and exhibited
a similar release pattern at all the temperatures initially. The
release of gemcitabine aer 48 h was 38% at 30 C, 59% at 37 CFig. 6 Metabolic stability of TPGS–Gem micelles in comparison to
native gemcitabine. Micellar gemcitabine or free gemcitabine (0.4mM)
was incubated in a buﬀer (pH 7.5) containing cytidine deaminase (10 ml,
speciﬁc activity 3.5 unit per mg) at 37 C (*P < 0.05, n ¼ 3).
This journal is © The Royal Society of Chemistry 2016and 64% at 40 C and a sustained released was observed
subsequently. The accumulative release at one week was
measured as 58% at 30 C, 89% at 37 C and 95% at 40 C. The
drug release study demonstrated that TPGS–Gem micelles were
able to sustain gemcitabine release at selected temperatures.
3.2 Stability studies with cytidine deaminase
Aer intravenous administration, gemcitabine undergoes
extensive metabolism to its inactive form, either intracellular or
extracellular, due to the activity of CDA.10 The stability of gem-
citabine in the micellar formulation was investigated aer
incubation with crude CDA in comparison with parent gemci-
tabine. The concentration of drug was quantied at various
time intervals using LC-MS/MS. As a function of incubation
time with cytidine deaminase, the concentration of gemcitabine
is shown in Fig. 7. The disappearance in the native gemcitabine
was observed time-dependently and only around 11% of gem-
citabine was detected aer 30 min of incubation. Whereas,
highly signicant resistant was observed in the gemcitabine
micellar formulation with more than 90% of gemcitabine can
be detected aer 30 min of incubation with crude CDA. This
modest degradation of gemcitabine in TPGS–Gem micelles
demonstrated the stability of formulation against CDA. These
results are in accordance with previous reports, suggested that
substitution of a 4-(N)-amino group of gemcitabine prevents
enzymatic degradation.20,47
3.3 In vitro cytotoxicity
The in vitro antiproliferative activity was performed by standard
MTT assay aer incubation of TPGS–Gemmicelles, gemcitabine
and placebo TPGS micelles with BxPC-3 cells as a modelRSC Adv., 2016, 6, 60126–60137 | 60133
Fig. 7 Release proﬁle of gemcitabine from TPGS–Gem micelles after
incubation in PBS (pH 7.4) for one week, at various temperatures i.e.
30, 37 and 40 C. The concentration of drug released at speciﬁc time
point was analyzed validated HPLCmethod (*P < 0.05, 30 C vs. 37 C/
40 C, after Bonferroni correction, n ¼ 3).
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View Article Onlinepancreatic cancer cell line at diﬀerent incubation points i.e. 24
h, 48 h, and 72 h (Fig. 8A–C respectively). Results suggested that
the various test samples exhibited dose and time dependent
cytotoxicity against BxPC-3 cells. It is noteworthy that placebo
TPGS micelles also showed signicant antiproliferative activity.
The TPGS–Gem micelles and placebo TPGS micelles showed
highly signicant growth inhibition of BxPC-3 cells aer 24 h as
compared to gemcitabine. The IC50 value of native gemcitabine
was evaluated as 165 8.65 mM at 24 h of incubation time while
the IC50 value of TPGS–Gem micelles was 6.13  0.35 mM, and
the IC50 value of the equivalent amount of placebo TPGSFig. 8 Percent of cell viability on diﬀerent concentrations of gemcitabin
drug conjugated, at equivalent weight as in TPGS–Gemmicelles) against
value obtained cells after incubation of samples at diﬀerent time points
gemcitabine/placebo TPGS micelles.
60134 | RSC Adv., 2016, 6, 60126–60137micelles was found to be 9.09  0.7 mM. Further, aer 48 h of
incubation with samples, a similar trend was observed and
TPGS–Gem micelles showed a signicant higher cytotoxicity as
compared to gemcitabine, however, the IC50 value of gemcita-
bine decreased massively to 2.4 0.23 mM, and the IC50 value of
TPGS–Gem micelles and placebo TPGS micelles was demon-
strated as 1.6  0.26 mM, 3.1  0.28 mM, respectively. A further
extend in the incubation time to 72 h, continued to decrease the
drug concentration necessary to 50% of growth inhibition. The
IC50 values were decreased to 0.27  0.1 mM, 0.6  0.22 mM, and
1.76  0.22 mM for gemcitabine, TPGS–Gem micelles, and
placebo TPGS micelles respectively. However, there a compa-
rable diﬀerence was showed in the IC50 value of gemcitabine
and TPGS–Gem micelles aer 72 h of incubation (Fig. 8D). The
enhanced cytotoxic eﬃcacy of gemcitabine could be due to the
intrinsic anticancer eﬃcacy of TPGS and/or stability of gemci-
tabine in micellar formulation against cytidine deaminase,
which can convert the monophosphorylated form of gemcita-
bine to an inactive metabolite.
3.4 Nucleoside transporter inhibition
Due to the highly hydrophilic character of gemcitabine, it relies
on the nucleoside transporter to cross the cellular lipid bilayer
and display its antiproliferative activity. A resistance mecha-
nism of gemcitabine includes deciency of nucleoside trans-
porters, causes decrease in the transport activity of drug into the
cell.48 Therefore, to assess the dependency of TPGS–Gem
micelles on nucleoside transporters like gemcitabine, a nucleo-
side transporter inhibition assay was performed. During MTTe, TPGS–Gem micelles and placebo TPGS micelles (i.e. TPGS with no
BxPC-3 cells at incubation time 24 h (A), 48 h (B) and 72 h (C). The IC50
(D). The results represent mean SD of three experiments. *P < 0.05 vs.
This journal is © The Royal Society of Chemistry 2016
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View Article Onlineassay, the cells were treated with dipyridamole, to block the
nucleoside transporter, prior to addition of various concentra-
tion of TPGS–Gem micelles and gemcitabine. The IC50 values
were determined against BxPC-3, pancreatic cancer cells aer
48 h of incubation (Table 1). The IC50 value of nativeFig. 10 Eﬀect of gemcitabine and TPGS–Gem micelles on the cellular
topography. The cells were treated with a 10 mM concentration of test s
ﬁxed by 2.5% of glutaraldehyde before images were captured under AFM
cell treated with TPGS–Gem micelles (arrow showing the pits on the su
Fig. 9 Demonstration of cellular uptake of TPGS–Gem micelles using
absence (D–F) of nucleoside transporter, dipyridamole. Micelles up-tak
showing blue ﬂuorescence. Images were captured using EVOS® Floid®
Table 1 Eﬀect of nucleoside transporter inhibitor on antiproliferative
activity of gemcitabine and TPGS–Gem micelles against BxPC-3 cell
lines following 48 h of incubation
Sample
BxPC-3 cells
IC50
(mM)
Relative gemcitabine
resistance
Gemcitabine 2.4 —
Gemcitabine + dipyridamole 11.9 5
TPGS–Gem micelles 1.6 —
TPGS–Gem micelles + dipyridamole 1.3 0.82
This journal is © The Royal Society of Chemistry 2016gemcitabine obtained aer treatment with dipyridamole was 11
mM, which is 5-fold higher than the IC50 value obtained with the
cell not treated with dipyridamole. However, when TPGS–Gem
micelles were treated with cells pre-incubated with dipyr-
idamole, there was no signicant change was observed in the
IC50 value. These results reect that TPGS–Gem micelles were
not dependent on nucleoside transporter to cross the cellular
lipid bilayer.3.5 Cellular uptake
The qualitative uptake of coumarin-6 loaded TPGS–Gem
micelles in BxPC-3 cells was determined in the presence and
absence of dipyridamole by measurement of uorescence.
Coumarin-6 was used as a uorescent marker to identify the
uptake of micelles in BxPC-3 cells. Fig. 9 shows the uptake of
TPGS–Gem micelles aer 4 h of incubation with BxPC-3 cells,
the green uorescence was due to the coumarin-6 loaded
micelles internalized by the cells. In order to conrm thatmorphology in human pancreatic cancer cell line (BxPC-3) by AFM
ample with respect to drug concentration in 6 well plates for 24 h and
. (A) Non-treated control cell, (B) cell treated with gemcitabine and (C)
rface of cell).
ﬂuorescence microscopy in BxPC-3 cell lines in presence (A–C) and
en by cells showing green ﬂuorescence and nuclei stained by DAPI
cell imaging station.
RSC Adv., 2016, 6, 60126–60137 | 60135
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View Article Onlineuorescence was present inside the cells, nucleus was counter
stained with a DAPI, a blue uorescent dye. The green uores-
cence adjacent to the nucleus conrming the micelles were
within the cells instead of attached to the cell surface.
Furthermore, nearly all cells either in presence (Fig. 9A) and
absence (Fig. 9D) of nucleoside transporter inhibitor were
stained with green uorescence suggesting that there was no
signicant diﬀerence in the uptake of micelles, suggesting that
in the micellar formulation gemcitabine does not dependent on
nucleoside transporters for internalization in the cells. These
results can be correlated with the insignicant change in the
IC50 values obtained aer inhibition of nucleoside transporters
by dipyridamole.3.6 AFM topography
To study the morphological changes in BxPC-3 cells aer
treatment with TPGS–Gemmicelles and native gemcitabine, the
cells were observed under atomic force microscope (AFM). The
control cells were treated with media only. It was observed that
the control cell had a smooth well-dened morphology and
showed an epithelial cell shape in general (Fig. 10A). The AFM
image of cell treated with native gemcitabine showed a smooth
surface, however, marked specic degenerative alteration in the
cell shape can be easily observed in the image (Fig. 10B). This
could be correlated with the higher IC50 value of the gemcita-
bine aer 24 h of incubation. Instead, in the AFM image of
TPGS–Gem micelles treated cell, several pits on the surface is
clearly visible and the morphology of cell was also transformed
(Fig. 10C). The small pits on the cells attributed the morpho-
logical alteration in response to TPGS–Gem micelles.49 The
ability to visualize cellular state is advantageous in order to
accurately demonstrate the eﬀect of these formulations on the
morphology and physiology. Although not qualitative these
provide a good tool to compliment the cytotoxicity studies and
provide insight into the likely fate of the cells. In this study the
presence of pitting indicated that cellular morphology has been
altered and perhaps cell membrane integrity has been
compromised. This indicates that the cells are not residing in
their ‘normal’ state. Hence, the observations of AFM topography
suggested the enhanced eﬃcacy of gemcitabine aer formation
of TPGS conjugated micelles.4. Conclusion
In the present investigation, TPGS–Gem prodrug was synthe-
sized and thoroughly characterised using analytical techniques.
The micelles of TPGS–Gem prodrug were prepared and char-
acterised for various physicochemical properties. The TPGS–
Gem micelles were evaluated against the determinants, which
hamper gemcitabine activity. The signicant resistance of
prepared micelles was observed against cytidine deaminase
which may lead to long circulation half-life of gemcitabine. The
prepared gemcitabine micelles exhibited enhanced anticancer
activity in the selected cell lines as compared to free gemcita-
bine. It is remarkable that unlike gemcitabine, TPGS–Gem
micelles were not relying on nucleoside transporter to cross the60136 | RSC Adv., 2016, 6, 60126–60137cellular lipid bilayer. Further, morphological studies suggested
the potential anticancer activity of TPGS–Gem micelles in vitro.
Moreover, our ndings provide a guideline for in vivo investi-
gations to conrm the feasibility of micellar formulation for
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